Capricor Thereutics将于7月29日举办与PPMD合作的网络研讨会，讨论Duchenne肌营养不良症的Deramiocel BLA进展和心肌病

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it will host a webinar in collaboration with Parent Project Muscular Dystrophy (PPMD) to review the current status of Capricor's Biologics License Application (BLA) for Deramiocel, provide information about cardiomyopathy in Duchenne, and take questions from the community. The webinar will be held on Tuesday, July 29, 2025, at 1:00 p.m. ET.